An Unusual Case of Metastatic Melanoma Sensitive to Chemotherapy and Immunotherapy, with Late Immune Escape in the Brain

Overview

Journal Cancer Immun

Specialties Allergy & Immunology
Oncology

Date 2008 Mar 28

PMID 18366150

Citations 2

Authors

Verena Voelter

Alessia Pica

Julien Laurent

Donata Rimoldi

Hanifa Bouzourene

Ali Sajadi

Maurice Matter

Pedro Romero

Nathalie Rufer

Daniel E Speiser

Affiliations

Soon will be listed here.

Citing Articles

Lymphatic-derived oxysterols promote anti-tumor immunity and response to immunotherapy in melanoma.

Sun M, Garnier L, Chevalier R, Roumain M, Wang C, Angelillo J Nat Commun. 2025; 16(1):1217.

PMID: 39890772 PMC: 11893137. DOI: 10.1038/s41467-025-55969-w.

microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.

Arts N, Cane S, Hennequart M, Lamy J, Bommer G, Van den Eynde B PLoS One. 2015; 10(4):e0122517.

PMID: 25853464 PMC: 4390329. DOI: 10.1371/journal.pone.0122517.

Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.

Iancu E, Baumgaertner P, Wieckowski S, Speiser D, Rufer N J Biomed Biotechnol. 2010; 2011:452606.

PMID: 21113290 PMC: 2989374. DOI: 10.1155/2011/452606.

References

Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini J, Valmori D . Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 2003; 63(17):5601-6. View

Lienard D, Rimoldi D, Marchand M, Dietrich P, van Baren N, Geldhof C . Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004; 4:4. View

Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok W, Speiser D . Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006; 177(10):6769-79. DOI: 10.4049/jimmunol.177.10.6769. View

Speiser D, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P . A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol. 2006; 177(2):1338-48. DOI: 10.4049/jimmunol.177.2.1338. View

Chapman P, Einhorn L, Meyers M, Saxman S, Destro A, Panageas K . Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17(9):2745-51. DOI: 10.1200/JCO.1999.17.9.2745. View

Wheeler C, Das A, Liu G, Yu J, Black K . Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 2004; 10(16):5316-26. DOI: 10.1158/1078-0432.CCR-04-0497. View

Rosenberg S . Shedding light on immunotherapy for cancer. N Engl J Med. 2004; 350(14):1461-3. PMC: 2275326. DOI: 10.1056/NEJMcibr045001. View

Ayyoub M, Hesdorffer C, Montes M, Merlo A, Speiser D, Rimoldi D . An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest. 2004; 113(8):1225-33. PMC: 385406. DOI: 10.1172/JCI20667. View

Antonia S, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006; 12(3 Pt 1):878-87. DOI: 10.1158/1078-0432.CCR-05-2013. View

10.

Ayyoub M, Merlo A, Hesdorffer C, Rimoldi D, Speiser D, Cerottini J . CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005; 174(8):5092-9. DOI: 10.4049/jimmunol.174.8.5092. View

11.

Speiser D, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F . Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115(3):739-46. PMC: 546459. DOI: 10.1172/JCI23373. View

12.

Gabrilovich D . Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol. 2007; 8(1):2-3. DOI: 10.1016/S1470-2045(06)70985-8. View

13.

Keilholz U, Punt C, Gore M, Kruit W, Patel P, Lienard D . Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005; 23(27):6747-55. DOI: 10.1200/JCO.2005.03.202. View

14.

Middleton M, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seiter S . Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18(1):158-66. DOI: 10.1200/JCO.2000.18.1.158. View